Press Room

12th American DDF Summit - Drug Delivery and Formulation

Start
Monday, September 26, 2022 - 09:00
End
Tuesday, September 27, 2022 - 18:00
Location: San Diego, USA
Booth Number: 13
Hovione is the Official Partner of the 12th DDF USA Summit 2022

 

HOVIONE PRESENTATION

 

Pedro Valente | Hovione

 

September 27th
“Solution Spotlights – Technology & Innovation” session
with Pedro Valente
R&D Director - Oral Drug Product Development

 

 

Download a copy of the presentation

 

 

Streamlining end-to-end amorphous formulation development into a tablet suitable for Continuous Direct Compression

 

  •  Learn how bioavailability enhancement of Amorphous Solid Dispersions (ASDs) can vary from one to three orders of magnitude by optimizing both ASD and tablet formulations and processes
  • Learn how state-of-the-art tools and methodologies can shorten time to Phase I/IND by accelerating formulation and development process 
  • Learn how Dispersome(R) technology, based on natural proteins derived from milk, broaden the formulation landscape enabling high drug load and high performing formulations
  • Learn how ASD formulations manufactured by spray drying can be designed to be directly compressible by Continuous Tableting
  • Learn more how Continuous Tableting is enabling disruptive innovations in the Pharma industry with respect to quality, scalability and improving supply chain flexibility and broadening Lifecycle Management options

 

 

At Hovione we are constantly innovating to find better and more efficient ways of doing things.
 

  • If you are developing a novel drug formulation or improving your drug candidate, learn how the Dispersome® technology can increase drug solubility with clear benefits for patients
     
  • If you are looking for the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying, learn more about ASD-HIPROS 
     

If you are interested in turning your most difficult challenge into a successful solution, schedule a meeting today to know how Hovione experts can support your project.

 

 

Find more at DDFSummit.com

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025